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Association of immunophenotype 
with expression of topoisomerase 
ii α and β in adult acute myeloid 
leukemia
Andrew p. Michelson1, Shannon McDonough2, cheryl L. Willman3, eric R. Koegle1, 
John e. Godwin4, Stephen H. petersdorf5,9, Alan f. List6, Megan othus2, 
frederick R. Appelbaum7, Jerald p. Radich7, Mahrukh K. Ganapathi8, Anjali S. Advani1* & 
Ram n. Ganapathi8*
Anthracyclines used in the treatment of acute myelogenous leukemia (AML) inhibit the activity of the 
mammalian topoisomerase ii (topo ii) isoforms, topo ii α and topo iiβ. In 230 patients with non-M3 AML 
who received frontline ara-C/daunorubicin we determined expression of topo IIα and topo iiβ by RT-
pcR and its relationship to immunophenotype (ip) and outcomes. treatment outcomes were analyzed 
by logistic or Cox regression. In 211 patients, available for analysis, topo IIα expression was significantly 
lower than topo iiβ (p < 0.0001). In contrast to topo IIα, topo iiβ was significantly associated with blast 
percentage in marrow or blood (p = 0.0001), CD7 (P = 0.01), CD14 (P < 0.0001) and CD54 (P < 0.0001). 
Event free survival was worse for CD56-negative compared to CD56-high (HR = 1.9, 95% CI [1.0–3.5], 
p = 0.04), and overall survival was worse for CD-15 low as compared to CD15-high (HR = 2.2, 95% CI 
[1.1–4.2], p = 0.02). Ingenuity pathway analysis indicated topo IIβ and immunophenotype markers 
in a network associated with cell-to-cell signaling, hematological system development/function and 
inflammatory response. Topo IIβ expression reflects disease biology of highly proliferative disease and 
distinct IP but does not appear to be an independent variable influencing outcome in adult AML patients 
treated with anthracycline-based therapy.
Standard induction therapy for acute myeloid leukemia (AML) consists of a combination of cytarabine (ara-C) 
and an anthracycline, such as daunorubicin or idarubicin1,2. While ara-C is a pyrimidine analogue that pre-
maturely terminates DNA polymerization, the anthracyclines are inhibitors of topoisomerase II3–6. DNA topoi-
somerases relieve the topological constraints associated with the double-helical structure of DNA during vital 
DNA metabolic processes, including DNA replication, transcription, chromosome segregation and recombina-
tion7. Mammalian topoisomerase II (topo II) consists of two isoforms, topo IIα (Mr 170 kDa) and topo IIβ (Mr 
180 kDa). Although the α and β topo II isoforms are highly homologous and catalyze similar biochemical reac-
tions, they are genetically distinct and exhibit different patterns of expression and cellular distribution7. While 
expression of topo IIα is cell cycle-dependent7 topo IIβ levels remain unchanged during cell cycle progression7–9 
and are maximal in terminally differentiated tissues8,10,11. This difference in expression suggests that these two 
isoforms exert distinct functional roles in cellular processes that require topological changes in the DNA mole-
cule. It has been suggested that topo IIα may be important for DNA replication, whereas topo IIβ may be involved 
in cellular differentiation8. Using stable expression of shRNA targeted to topo IIα or topo IIβ, in cell culture 
models of human AML, we have been able to demonstrate a functional role for topo IIβ in apoptosis following 
all-trans-retinoic acid induced differentiation12. Further, our studies have demonstrated that clinically active drugs 
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target different isoforms of topo II to exert their anti-tumor activity and that topo IIα and topo IIβ cooperate 
to maintain genome stability, which may be modulated by their C-terminal domain13.
Although topo II is a putative target of daunorubicin that is a key component of the induction treatment reg-
imen for AML for over 3 decades, the significance of topo II α and β isoform expression and its association with 
other biomarkers related to outcome has not been satisfactorily addressed. Analysis of topo IIα expression have 
suggested correlations between gene amplification of topo IIα and response to anthracycline chemotherapy in 
breast cancer14. Some reports indicate no significant predictive value of topo IIα expression levels, while others 
suggest that topo IIα expression can predict treatment failure15–19. In contrast to the focus on topo IIα in AML 
the expression of topo IIβ that is targeted by daunorubicin and idarubicin has not been satisfactorily addressed. 
Topo IIβ expression has been proposed to have a role in resistance to drugs that target this isoform20,21 and in 
resistance to all-trans retinoic acid (ATRA) induced differentiation in M3 AML22. Interestingly, mitoxantrone that 
targets topo IIβ and other topo II inhibitors have been suggested to be involved in therapy related leukemia23. In 
the present study, we examined the expression of the topo II isoforms and possible relationships of topo IIα and 
topo IIβ expression to immunophenotype (IP) and outcomes in de novo and secondary adult AML blast samples 
from 230 patients enrolled in 4 SWOG studies who received ara-C/daunorubicin-based frontline chemotherapy.
Results
correlation of topo iiα and topo iiβ expression with clinical characteristics and immunophe-
notype markers. Of the 230 treatment-naïve specimens available, topo II expression data from 211 patients 
was available for analysis. Patient and clinical characteristics for the 211 patients are summarized in Table 1. 
Expression (ΔCt) of the topo II isoforms was positively correlated (Fig. 1) and topo IIβ expression was on average 
2.2-fold higher than topo IIα expression (CI 1.8–2.6, p < 0.001).
Association of topo IIα or β expression with clinical characteristics is outlined in Table 2. Topo IIα expression 
was not found to be significantly associated with any patient or disease characteristic in univariate analyses. In 
contrast, topo IIβ expression was inversely associated with age (p = 0.001) and positively associated with both 
marrow and peripheral blast percentage (p < 0.001). Topo IIβ expression also varied significantly among FAB 
classes, being highest for M0 and lowest for M4 and M7 (p = 0.0012). Since immunophenotype is associated 
with outcome, analysis of the correlation of topo IIα or β expression with IP markers was carried out and is out-
lined in Table 3. Topo IIα expression was not correlated with any of the immunophenotypic markers measured. 
In contrast, topo IIβ expression was associated with expression of CD4 (p = 0.0025), CD7 (p = 0.01), CD11a 
(p < 0.0001), CD11b (p < 0.0001), CD11c (p = 0.007), CDw14 (p < 0.0001), CD15 (p = 0.045), CD16 (p = 0.009), 
CD34 (p = 0.03), CD54 (p < 0.0001) and HLA-DR (p < 0.0003). In multivariate analysis of 137 patients with com-
plete data, topo IIβ expression was positively associated with age, as well as blood and marrow blast percentage 
(p < 0.001). Additional regression analysis of IP with outcome measures revealed event free survival was worse 
for CD56-ve compared to CD56-high (HR = 1.9, 95% CI [1.0–3.5], p = 0.04), and overall survival was worse for 
CD15-low as compared to CD15-high (HR = 2.2, 95% CI [1.1–4.2], p = 0.02). Neither topo IIα expression nor 
topo IIβ expression was significantly associated with clinical outcomes (CR, RD, RFS and OS) in uni- or multi-
variate analysis.
Data from analysis of P-glycoprotein expression and function, representing possible determinants of resist-
ance was available and correlation with topo II isoform expression was assessed. Topo IIβ expression was weakly 
correlated with P-glycoprotein expression detected with the MM4.17 antibody (p = 0.07) and P-glycoprotein 
function based on rhodamine efflux (p = 0.04). Both parameters were inversely related to topo IIβ expression 
but not correlated with topo IIα expression. However, in univariate analysis neither P-glycoprotein expression or 
function was associated with OS, RFS or EFS.
pathway analysis of immunophenotype markers with topo iiα and topo iiβ. Ingenuity pathway 
analysis of drug pharmacodynamic targets, immunophenotype markers and topo II are outlined in Figs. 2 and 3. 
In Fig. 2, among 6 networks the major network with a score of 34 and 15 focus molecules identified the direct 
interaction of topo IIα/topo IIβ and cell-to-cell signaling, hematological system development/function and 
immune cell trafficking as the top diseases and functions. In Fig. 3, with a focus on topo IIβ and the significantly 
associated immunophenotype markers, among 3 networks the major network generated a score of 25 with 9 focus 
molecules and an association with cell-to-cell signaling/interaction, hematological system development/func-
tion and inflammatory response among the top diseases and functions. Overall, both networks identified similar 
functional events and disease states based on the interaction between significantly associated immunophenotype 
markers and topo II.
Discussion
This is the first study examining the expression levels of both topo IIα and IIβ in a large cohort of de novo and 
secondary AML patients and evaluating associations between topo II isoform expression, clinical outcome, immu-
nophenotype and other patient characteristics. Inhibitors of topo II, such as the anthracyclines, are the corner-
stones of AML treatment and presumed primarily to target topo IIα. Despite the importance of the anthracyclines 
at inducing complete remission, it is unknown if the expression levels of topo IIα can predict clinical outcome. 
Present results do demonstrate a significant inter-individual variability in topo IIα mRNA levels and failed to show 
any significant association between topo IIα expression and any disease characteristic in de novo and secondary 
AML patients. It has been shown that exposure of AML blast cells to the anthracyline daunorubicin promotes 
expansion of topo IIα negative cells19. This ex-vivo observation, on daunorubicin-treatment dependent selection 
of topo IIα negative cells was however, not linked to clinical outcome. Despite active investigation into the clinical 
significance of topo IIα, little is known about the importance of topo IIβ in AML. Gieseler et al.24 reported that 
blast cells from patients with elevated activity of topo IIβ expressed reduced sensitivity in vitro to daunorubicin or 
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idarubicin and relapse from treatment with anthracyclines may be linked to a significantly lower topo IIα/β ratio. 
Our studies in HL-60 cells with targeted stable down-regulation of topo IIα or β isoform or in models engineered 
to express either topo IIα or topo IIβ, indicate that while sensitivity to doxorubicin is unaltered, a 2- to 4-fold 
reduction in etoposide sensitivity is observed following down-regulation of the α isoform, and a marked decrease 
in sensitivity to amsacrine, idarubicin and mitoxantrone is seen in cells depleted of the β isoform12,13. However, 
Characteristics Median Range
Age (yrs) 64 19–88
Marrow blasts (%) 70 4–99
WBC (109/L) 29.6 0.8–274
Peripheral blasts (%) 38 0–99
Hemoglobin (g/dL) 9.1 4.3–13.7






   Native American 1 0.5
   Asian, Pacific Islander 7 3
   Black, African American 17 8
   White/Hispanic 5 2
   White/Non-Hispanic 179 85
   Hispanic, NOS 2 1
AML Onset (months):
   De Novo 170 81
   Secondary 41 19






























Table 1. Characteristics of 211 adult patients with previously untreated (N = 211) non-M3-AML. *Percentages 
for karyotype categories are based on patients with cytogenetics evaluated.
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topo IIβ was significantly associated with several factors that have been associated with favorable outcomes in 
AML, such as younger age, low CD4, CD14, CD16, CD54, CD11b, and HLA-DR, as well as with unfavorable fac-
tors, high peripheral and marrow blast percentage and increased CD7 expression. While reports on relationship or 
precise role of immunophenotype and prognosis in AML is controversial25–29, the association with topo IIβ but not 
topo IIα expression and proposed network of topo IIβ with immunophenotype markers suggests a potential role 
for topo IIβ expression and immunophenotype in the biology of AML. Song et al.30 reported high topo IIβ/topo IIα 
expression to be correlative with favorable outcome but this observation could not be compared with the present 
results since induction therapy utilized the anthracycline idarubicin and most patients also received hematopoi-
etic stem cell transplantation. Recent reports31,32 on use of idarubicin in adult AML indicate: (a) that an increased 
cumulative dose of idarubicin during consolidation can improve leukemia-free survival; and (b) comparing ida-
rubicin to high dose daunorubicin during induction did not indicate significant differences in CR rate, relapse and 
survival. Heterogeneity in development of resistant cells as well as differential expression in key pathways has been 
suggested to involved in refractory AML33,34. Analysis of topo II α and β expression coupled with immunopheno-
type in AML cells from patients with disease that is resistant to anthracycline/cytarabine therapy might provide 
insights on biomarkers relevant to outcome. In summary, topo IIβ expression reflects aspects of disease biology, 
such as highly proliferative disease (higher blasts) and immunophenotypic differences but does not appear to be 
an independent variable influencing outcome in adult AML patients treated with anthracycline-based therapy.
Materials and Methods
patients and specimens. Bone marrow (BM) specimens were provided by the SWOG AML/MDS 
Repository for 230 adult patients with non-M3 AML by FAB criteria who were enrolled during 1992–1998 for 
ara-C/daunorubicin-based frontline chemotherapy on any of four SWOG studies S9031, S9126, S9333 and S9500. 
Specimens of cryopreserved BM cells and expected to contain >70% blasts, were used when available, otherwise 
RNA extracted from specimens upon receipt at the repository were used. All patients provided written informed 
consent in accordance with institutional and federal guidelines. The protocol was approved by the Cleveland 
Clinic IRB CC 937: S9031-S9126-S9333-S9500-B Topoisomerase 2 Expression and Acute Myeloid Leukemia 
(AML).
The study was performed in accordance with the Declaration of Helsinki.
RnA extraction. RNA extraction was performed on the entire BM specimen using the Trizol reagent 
(Invitrogen USA) per the manufacturer’s instructions. The RNA pellets were re-suspended in 50 μL RNase-free 
water and stored at −80 °C.
qRT-PCR. RNA (1500 ng) was reverse transcribed to cDNA and used for quantitative PCR reaction, which 
was carried out in triplicate at the Case Comprehensive Cancer Center, Gene Expression Core Facility using 
an ABI PRISM 7900HT (Martina Veigl, Director). The primers used for the PCR reaction were: topo IIα (for-
ward: 5′-TGTCTCTCAAAAGCCTGATC-3′, reverse: 5′-GTCCATATGGAAGTCATCAC-3′), topo IIβ (for-
ward: 5′-TAAAGGCCGAGGGGCAAAGA-3′, reverse: 5′-GCAGAGAAGGTGGCTCAGTA-3′) specific 
primers and β2-microglobulin (B2MG) (forward: 5′-CTTGTCTTTCAGCAAGGACTGG-3′ and reverse: 
5′-CATGATGCTGCTTACATGTCTC-3′primers). B2MG was used as an endogenous control to normalize topo 
IIα and topo IIβ expression.
immunophenotypic and cytogenetic analysis. Immunophenotyping was performed at the SWOG 
AML/MDS Repository at the University of New Mexico (Cheryl Willman, Director). Blast cells were assessed for 
expression, of the following IP markers: CD2, CD4, CD7, CD8, CD11a, CD11b, CD11c, CD13, CDW14, CD15, 
CD16, CD18, CD19, CD33, CD34, CD38, CD44, CD54, CD56 and HLA-DR. Expression of these markers in 
Figure 1. Topoisomerase II expression by topo II isoform in pre-treatment marrow specimens from 211 adult 
AML patients. The delta Ct (ΔCt) was calculated by subtracting the average cycle threshold (Ct) for each topo 
II isoform from the average β2-microglobulin (Ct). “V” indicates censored data. Solid lines show mean relative 
expression (ΔCt) and 95% confidence interval. Mean relative expression was 2.2-fold higher for topo IIβ 
compared to topo IIα.
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the total population was characterized as negative, high, low, low/high or low/negative. Four other markers were 
assayed but excluded from this analysis: CD3, CD8 were negative for all patients; CD38 and CD45 were highly 
expressed in all but 2 patients. Cytogenetic studies of pretreatment marrow or peripheral blood were performed 
at SWOG-approved laboratories and centrally reviewed by the SWOG Cytogenetics Committee.
Statistical and pathway analysis. The ΔCt for topo IIα or IIβ RNA was calculated by subtracting the 
average cycle threshold (Ct) for each topo II isoform from the average β2-microglobulin (Ct). Average topo II 
Pts.
Topo IIα ΔCt Topo IIβ ΔCt
aMean 95% CI P* aMean 95% CI P*
Sex F 94 4.6263 (4.2279, 5.0248) 0.26 3.3033 (3.0780, 3.5287) 0.62
M 117 4.3317 (3.9978, 4.6656) 3.3768 (3.1880, 3.5656)
Race Asian 7 3.4503 (0.8010, 6.0996) 0.52 4.1253 (2.8630, 5.3877) 0.25
Black 17 4.6634 (4.0769, 5.2499) 3.5518 (3.0479, 4.0557)
N.A./A.A.** 1 4.5682 NA 3.3044 NA
White 184 4.4968 (4.2205, 4.7730) 3.3020 (3.1487, 3.4553)
Unknown 2 3.1383 (−2.9872, 9.2638) 2.7353 (−2.7070, 8.1776)
Hispanic No 204 4.4853 (4.2234, 4.7472) 0.35 3.3421 (3.1947, 3.4895) 0.88
Yes 7 3.8123 (2.7032, 4.9213) 3.4018 (2.5783, 4.2252)
Secondary No 170 4.4411 (4.1584, 4.7238) 0.73 3.2957 (3.1359, 3.4555) 0.18
AML Yes 41 4.5534 (3.9369, 5.1700) 3.5445 (3.2064, 3.8826)
SWOG S9031 75 4.7364 (4.4125, 5.0603) 0.19 3.3004 (3.0788, 3.5220) <0.0001
trial S9126 10 5.1018 (3.5095, 6.6940) 4.1963 (3.5343, 4.8583)
S9333 81 4.3295 (3.8460, 4.8130) 3.5950 (3.3656, 3.8245)
S9500 45 4.1055 (3.5477, 4.6632) 2.7758 (2.4663, 3.0852)
Year of 1992 32 4.8509 (4.4034, 5.2984) 0.24 3.4673 (3.1730, 3.7616) 0.076
entry 1993 35 4.6456 (4.0938, 5.1973) 3.1022 (2.7214, 3.4831)
into 1994 11 5.2779 (4.0656, 6.4903) 3.9856 (3.2767, 4.6945)
trial 1995 20 4.2586 (3.4299, 5.0874) 3.4189 (2.8697, 3.9680)
1996 51 3.9532 (3.3684, 4.5380) 3.2415 (2.9486, 3.5344)
1997 42 4.4320 (3.9085, 4.9554) 3.1622 (2.8130, 3.5114)
1998 20 4.6438 (3.3084, 5.9791) 3.7860 (3.3334, 4.2387)
FAB M0 9 4.5263 (2.6133, 6.4393) 0.85 2.4874 (1.6527, 3.3221) 0.0012
class M1 48 4.3428 (3.9809, 4.7048) 3.0910 (2.8157, 3.3664)
(local M2 78 4.3830 (3.9286, 4.8374) 3.2699 (3.0202, 3.5196)
diagnosis) M4 46 4.6417 (3.9839, 5.2995) 3.7800 (3.4969, 4.0630)
M5 22 4.2870 (3.5581, 5.0158) 3.6301 (3.2513, 4.0088)
M6 1 5.6905 NA 3.0522 NA
M7 2 4.1100 (3.0501, 5.1699) 3.7085 (−0.892, 7.5062)
Other 5 5.2328 (2.6278, 7.8377) 3.5783 (1.8490, 5.3077)
Cytogenetic Favorable 14 4.2439 (2.6233, 5.8644) 0.66 3.7951 (3.1936, 4.3965) 0.34
risk group Int-Normal 78 4.3503 (3.8822, 4.8184) 3.2937 (3.0178, 3.5696)
Int-II 51 4.7509 (4.3165, 5.1852) 3.4822 (3.2511, 3.7132)
Unfavorable 26 4.4781 (3.9370, 5.0193) 3.2704 (3.8841, 3.6566)
Pts bCoeff. 95% CI P* bCoeff. 95% CI P*
Age (years) 211 0.00633 (−0.0112, 0.0239) 0.48 0.0163 (0.0067, 0.0260) 0.001
Marrow blasts (%) 196 −0.00167 (−0.0141, 0.0108) 0.79 −0.0165 (−0.0230, −0.0101) <0.0001
WBC (109/L) 211 0.00089 (−0.0041, 0.0059) 0.73 −0.0009 (−0.0037, 0.0020) 0.55
Peripheral blasts (%) 202 0.00054 (−0.0079, 0.0090) 0.90 −0.0123 (−0.0167, −0.0078) <0.0001
Hemoglobin (g/dL) 206 0.01830 (−0.1297, 0.1663) 0.81 −0.0048 (−0.0876, 0.0781) 0.91
Platelets (109/L) 210 0.00157 (−0.0011, 0.0042) 0.25 0.0016 (0.0001, 0.0031) 0.04
Table 2. Topo IIα and IIβ expression by clinical characteristics of 211 treatment-naïve adult non-M3 AML 
patients. Abbreviations: Pts. = patients; CI = confidence interval. aMeans (and 95% CI of the means), represent 
mean ΔCt calculated for the listed subgroup. bCoeff. represents the coefficient (and associated 95% CI) from a 
univariate linear regression model with the ΔCt variable as the outcome and the listed variables as covariates. 
Coeff. greater than 0 indicates a positive association: as the covariate values increase, the ΔCt values increase 
on average. Coeff. less than 0 indicates a negative association; as the covariate values increase, the ΔCt values 
decrease on average. *P-value for heterogeneity of mean ΔCt among categories or regression on continuous 
variables; calculated from univariate linear regression models with ΔCt as the outcome and each variable as a 
covariate. **N.A./A.A.: Native America or Alaskan Native.
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Immunophenotype * Pts.
Topo IIα ΔCt Topo IIβ ΔCt
Mean 95% CI P** Mean 95% CI P**
CD2 HIGH/LOW 10 4.2453 (3.3954, 5.0952) 0.67 2.8719 (1.9956, 3.7486) 0.14
NEGATIVE 176 4.5147 (4.2180, 4.8114) 3.3844 (3.2255, 3.5432)
CD4 HIGH 16 4.1362 (3.2256, 5.0468) 0.50 3.7466 (3.3509, 4.1423) 0.0025
LOW 41 4.7695 (4.2694, 5.2695) 3.7716 (3.4116, 4.1316)
NEGATIVE 129 4.4598 (4.0953, 4.8242) 3.1766 (2.9935, 3.3597)
CD7 HIGH 23 3.9183 (3.1032, 4.7334) 0.27 2.8087 (2.4433, 3.1742) 0.010
LOW 21 4.8258 (4.1192, 5.5324) 3.6811 (3.2225, 4.1396)
NEGATIVE 140 4.5218 (4.1847, 4.8589) 3.4168 (3.2357, 3.5978)
CD11A HIGH 109 4.4966 (4.1603, 4.8328) 0.57 3.6105 (3.4184, 3.8027) 0.0002
LOW 48 4.3216 (3.6616, 4.9816) 3.1290 (2.8229, 3.4351)
NEGATIVE 29 4.8095 (4.0099, 5.6091) 2.7802 (2.3649, 3.1954)
CD11B HIGH 41 4.8756 (4.3956, 5.3556) 0.30 4.0955 (3.8647, 4.3263) <0.0001
LOW 25 4.6374 (3.8819, 4.7239) 3.0996 (2.7450, 3.4541)
NEGATIVE 120 4.3434 (3.9628, 2.9839) 3.1580 (2.9567, 3.3593)
CD11C HIGH 94 4.5009 (4.1292, 4.8727) 0.88 3.5975 (3.3765, 3.8185) 0.007
LOW 48 4.3987 (3.7782, 5.0193) 3.0564 (2.7458, 3.3669)
NEGATIVE 44 4.6093 (3.9745, 5.2442) 3.1704 (2.8697, 3.4710)
CD13 HIGH 134 4.3263 (3.9917, 4.6609) 0.12 3.3823 (3.2031, 3.5615) 0.42
LOW 34 5.0728 (4.4835, 5.6621) 3.4227 (3.0434, 3.8019)
NEGATIVE 18 4.7135 (3.5730, 5.8540) 3.0426 (2.4036, 3.6815)
CDw14 HIGH 34 4.7128 (4.0369, 5.3887) 0.55 4.2883 (4.0132, 4.5633) <0.0001
LOW 17 4.8316 (3.9607, 5.7026) 3.7438 (3.2190, 4.2687)
NEGATIVE 135 4.4049 (4.0647, 4.7451) 3.0735 (2.9024, 3.2445)
CD15 HIGH 97 4.4044 (4.0045, 4.8042) 0.79 3.5449 (3.3310, 3.7589) 0.045
LOW 23 4.5911 (3.8205, 5.3617) 3.1579 (2.7509, 3.5649)
NEGATIVE 66 4.6094 (4.1177, 5.1010) 3.1497 (2.8760, 3.4233)
CD16 HIGH/LOW 7 5.8795 (4.2576, 7.5014) 0.06 4.3967 (3.4498, 5.3454) 0.009
NEGATIVE 179 4.4463 (4.1585, 4.7340) 3.3161 (3.1593, 3.4729)
CD18 HIGH 121 4.3574 (4.0092, 4.7057) 0.06 3.4947 (3.3033, 3.6860) 0.058
LOW 34 4.3074 (3.5520, 5.0629) 3.0955 (2.7007, 3.4902)
NEGATIVE 30 5.2622 (4.6282, 5.8963) 3.0977 (2.7122, 3.4831)
CD19 HIGH/LOW 6 5.2026 (3.2847, 7.1204) 0.37 3.4779 (2.4885, 4.4673) 0.78
NEGATIVE 180 4.4768 (4.1881, 4.7655) 3.3528 (3.1931, 3.5124)
CD33 HIGH 159 4.4490 (4.1326, 4.7654) 0.59 3.3184 (3.1443, 3.4925) 0.50
LOW 23 4.7134 (4.0052, 5.4216) 3.5973 (3.2237, 3.9708)
NEGATIVE 4 5.3101 (4.0324, 6.5878) 3.5012 (2.1531, 4.8492)
CD34 HIGH 106 4.6027 (4.2370, 4.9685) 0.07 3.5299 (3.3438, 3.7159) 0.03
LOW 6 2.6970 (0.6967, 4.6972) 2.7758 (1.5067, 4.0448)
NEGATIVE 74 4.4996 (4.0361, 4.9630) 3.1560 (2.8823, 3.4298)
CD44 HIGH 182 4.4889 (4.2018, 4.7760) 0.74 3.3482 (3.1893, 3.5072) 0.40
LOW/NEGATIVE 3 4.8630 (−0.9289, 10.655) 3.8840 (2.2043, 5.5638)
CD54 HIGH-SUB 11 4.8624 (4.2678, 5.4571) 0.32 3.8084 (3.4275, 4.1893) <0.0001
HIGH-TOT 47 4.8973 (4.3107, 5.4840) 3.5599 (3.2425, 3.8773)
LOW-TOT 64 4.2672 (3.7429, 4.7916) 3.6311 (3.3984, 3.8638)
NEGATIVE 63 4.3619 (3.8810, 4.8428) 2.8482 (2.5649, 3.1315)
CD56 HIGH 27 4.6836 (3.8938, 5.4734) 0.60 3.6942 (3.2065, 4.1818) 0.20
LOW 5 3.7128 (0.1725, 7.2530) 3.4801 (2.1129, 4.8474)
NEGATIVE 154 4.4936 (4.1865, 4.8007) 3.2937 (3.1272, 3.4601)
HLA-DR HIGH 154 4.4355 (4.1422, 4.7287) 0.58 3.4844 (3.3177, 3.6511) 0.0003
LOW 5 5.0998 (2.3465, 7.8532) 3.5153 (2.3476, 4.6829)
NEGATIVE 27 4.7585 (3.7570, 5.7600) 2.5996 (2.2039, 2.9952)
Table 3. Topo IIα and IIβ expression by immunophenotype markers of 186 treatment-naïve adult non-M3 
AML patients. Abbreviations: Pts = patients; CI = confidence interval. *Expression of immunophenotype 
markers was originally classified as high in the total blast population (HIGH-TOT) or a subpopulation 
(HIGH-SUB), low in the total blast population (LOW-TOT) or a subpopulation (LOW-SUB), or negative. 
These categories were combined as needed to ensure adequate category sizes for comparisons when possible. 
**P-value for heterogeneity of mean ΔCt among immunophenotype categories calculated from univariate 
linear regression models with ΔCt as the outcome and each immunophenotype marker as the covariate; means 
and 95% CIs of the means of ΔCt were calculated for each subgroup listed.
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Figure 2. Ingenuity pathway analysis of drug pharmacodynamic targets, associated immunophenotype 
markers and topo II. The (—) and (---) lines in network represent direct and in indirect interaction, respectively. 
Gene ID is identified in the network symbols and symbol key describes biological relevance. Gray fill color in 
symbols identifies focus genes from the dataset.
Figure 3. Ingenuity pathway analysis of topo IIβ and significantly associated immunophenotype markers. The 
(—) and (---) lines in network represent direct and in indirect interaction, respectively. Gene ID is identified in 
the network symbols and symbol key describes biological relevance. Gray fill color in symbols identifies focus 
genes from the dataset.
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expression of 40 was considered right-censored. Topo IIα expression was censored on four observations and topo 
IIβ expression on three observations.
Clinical data (age, sex, race/ethnicity, secondary versus de novo AML onset, FAB classification, cytogenetics, 
marrow and peripheral blood blast percentages, WBC and PLT counts, and hemoglobin) and treatment outcomes 
were collected and evaluated per standard SWOG procedures as part of the clinical trials on which the patients 
participated. Complete response (CR) and resistant disease (RD) were defined by standard criteria35. Overall 
survival (OS) was measured from date of study entry until death from any cause, with observation censored at the 
date of last contact for patients last known to be alive. Relapse-free survival (RFS) was measured from the date 
of achieving CR until relapse or death from any cause, with observation censored at the date of last contact for 
patients last known to be alive without report of AML relapse. Linear regression models were used to examine the 
effects of patient characteristics and immunophenotype on expression. The effects of expression and other patient 
characteristics on treatment outcomes were investigated using logistic (CR, RD) and proportional hazards (OS, 
RFS) regression analyses.
Multivariate analyses for the outcomes of OS, RFS, RD, and CR accounted for clinical and immunophenotype 
characteristics. Additional factors were excluded as needed to fit each model: expression of CD2, CD19, CD56, 
and HLA-DR on CR; expression of CD2, CD19, CD54, CD56, and HLA-DR on RD; expression of CD54 on OS; 
and expression of CD2, CD4, CD11a, CD16, CD19, C33, CD44, CD54, CD56, and HLA-DR on RFS.
Ingenuity pathway analysis (Qiagen Inc.) of target molecules identified for significant association with topo 
II α/β isoform expression was carried out using version 46901286 (11–21–2018). Ingenuity pathway analysis was 
carried out using: (a) drug pharmacodynamic targets, associated immunophenotype markers and topo II α/β; 
and (b) topo IIβ and significantly associated immunophenotype markers.
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